Bio-Rad Laboratories (NYSE:BIO.B) Stock Passes Below 200 Day Moving Average – Should You Sell?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $291.14 and traded as low as $267.43. Bio-Rad Laboratories shares last traded at $267.43, with a volume of 18 shares trading hands.

Bio-Rad Laboratories Price Performance

The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The business’s 50-day simple moving average is $273.89 and its 200 day simple moving average is $291.14. The firm has a market capitalization of $7.16 billion, a P/E ratio of 44.06 and a beta of 0.96.

Bio-Rad Laboratories (NYSE:BIO.B) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.